Recruiting PHASE1/PHASE2 INTERVENTIONAL 10-arm NCT06932523

A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Randomized, Blinded, Controlled Phase I/Ⅱ Clinical Trial Evaluating the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) for Healthy Individuals Aged 40 Years and Above

Sponsor: Shanghai Institute Of Biological Products

Conditions Herpes Zoster (HZ)

Interventions High-dose adjuvant Low-dose adjuvant Normal Saline Recombinant herpes zoster vaccine with high-dose adjuvant Recombinant herpes zoster vaccine with low-dose adjuvant Shingrix (GSK)

Updated 2 times since 2025 Last updated: Jan 5, 2026 Started: Apr 4, 2025 Primary completion: Jun 30, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Herpes Zoster (HZ) and is currently actively recruiting participants. Shanghai Institute Of Biological Products leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
May 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Apr 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Institute Of Biological Products

Data source: Shanghai Institute Of Biological Products

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China